Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20162129 | 0.99 | MELK (0.45) | MELKS1PR1F2PLGPLAU | |
| SCHEMBL20162149 | 0.86 | MAP3K5 (0.34) | MELKS1PR1KLKB1MLNR | |
| SCHEMBL20162140 | 0.85 | WNT1 (0.38) | KLKB1MLNR | |
| Hydrochloric Acid SCHEMBL21518081 | 0.82 | PLAU (0.42) | PLAU | |
| SCHEMBL20162120 | 0.81 | TAS2R8 (0.49) | MELKF2PLGPLAUPLAT | |
| SCHEMBL20162172 | 0.80 | TAS2R8 (0.35) | MLNR | |
| SCHEMBL20367451 | 0.79 | HDAC1 (0.38) | MELKS1PR1KLKB1MLNR | |
| SCHEMBL20162145 | 0.78 | SCD (0.39) | KLKB1MLNR | |
| SCHEMBL20162118 | 0.78 | TAS2R8 (0.36) | MLNR | |
| SCHEMBL20367291 | 0.77 | ESR2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | claimed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | claimed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | MELK 3923/4885S1PR1 2396/4885F2 3104/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | MELK 3847/4885S1PR1 1987/4885F2 4800/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | MELK 3923/4885S1PR1 2396/4885F2 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.